Archives de la catégorie : 2026

Osivax Reports Phase 2b Results for OVX836 and Advances Combination Strategy for Next-Generation Seasonal Influenza Vaccines Phase 2b study provides first consistent efficacy signal for a monovalent nucleoprotein-based influenza vaccine across both major influenza A subtypes  OVX836 did not meet its pre-specified primary endpoint of 50% vaccine efficacy Results support development of OVX836 in combination …

Continuer la lecture « Osivax Reports Phase 2b Results for OVX836 and Advances Combination Strategy for Next-Generation Seasonal Influenza Vaccines »

Osivax and GC Biopharma Enter Strategic Collaboration to Develop a Next-Generation Influenza Vaccine Combining OVX836 and GC FLU Combines Osivax’s proprietary OVX836 T-cell vaccine and technology with GC Biopharma’s marketed influenza vaccine and worldwide manufacturing expertise  Positions Osivax as the global development lead for a differentiated next-generation influenza vaccine candidate Aims to deliver enhanced and …

Continuer la lecture « Osivax and GC Biopharma Enter Strategic Collaboration to Develop a Next-Generation Influenza Vaccine »

Osivax Partners with CEPI to Advance T-cell Immunity using World-First Adjuvant Library Access to CEPI’s Adjuvant Library to assess dose-sparing potential of adjuvanted formulations of OVX836 vaccine in flu pandemic settings  Potential to maximize vaccine supply and broaden global access in emergencies, while maintaining a non-adjuvanted OVX836 core development path Lyon, France and Liège, Belgium – …

Continuer la lecture « Osivax Partners with CEPI to Advance T-cell Immunity using World-First Adjuvant Library »